Current research status on HER2 protein expression levels and the efficacy of targeted therapy in breast cancer.

Front Oncol · 2025 · PMC12256218 · PMID 40661775

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Subgroup analysis showed a trend towards higher pathologic complete response (pCR) rates in HER2 IHC3+ patients compared to HER2 IHC2+/ISH+ patients (34/56, 60.7% vs 4/13, 30.8%).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.